Literature DB >> 21998414

Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.

Mark A Miller1, Ruth Blanchette, Patrizia Spigaglia, Fabrizio Barbanti, Paola Mastrantonio.   

Abstract

We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180 Clostridium difficile clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, >16 μg/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new rpoB mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21998414      PMCID： PMC3233014          DOI： 10.1128/JCM.05100-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  24 in total

1.  Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains.

Authors:  Warren N Fawley; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

2.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Treatment of clostridium difficile infection.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2011-02-21       Impact factor: 1.909

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

7.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

Authors:  Carmelo Scarpignato; Iva Pelosini
Journal:  Chemotherapy       Date:  2005       Impact factor: 2.544

10.  Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats.

Authors:  L Cellai; M Colosimo; E Marchi; A P Venturini; G Zanolo
Journal:  Chemioterapia       Date:  1984-12
View more
  11 in total

1.  Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013).

Authors:  Stefano Di Bella; Alexander W Friedrich; Esther García-Almodóvar; Maria Serena Gallone; Fabrizio Taglietti; Simone Topino; Vincenzo Galati; Emma Johnson; Silvia D'Arezzo; Nicola Petrosillo
Journal:  BMC Infect Dis       Date:  2015-04-22       Impact factor: 3.090

Review 2.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

3.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

Review 5.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

6.  In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.

Authors:  Robert J Carman; James H Boone; Harish Grover; Kimberly N Wickham; Li Chen
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.

Authors:  P Lutz; M Parcina; I Bekeredjian-Ding; A Hoerauf; C P Strassburg; U Spengler
Journal:  Infection       Date:  2013-03-25       Impact factor: 3.553

Review 8.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267

9.  Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections.

Authors:  Jacqueline Färber; Sebastian Illiger; Fabian Berger; Barbara Gärtner; Lutz von Müller; Christoph H Lohmann; Katja Bauer; Christina Grabau; Stefanie Zibolka; Dirk Schlüter; Gernot Geginat
Journal:  Antimicrob Resist Infect Control       Date:  2017-02-15       Impact factor: 4.887

Review 10.  Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance.

Authors:  Priscilla A Johanesen; Kate E Mackin; Melanie L Hutton; Milena M Awad; Sarah Larcombe; Jacob M Amy; Dena Lyras
Journal:  Genes (Basel)       Date:  2015-12-21       Impact factor: 4.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.